92 citations
,
December 2012 in “Current opinion in genetics & development” Turing patterns are now recognized as important in developmental biology.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
January 2018 in “Elsevier eBooks” 5α-reductase-2 deficiency causes ambiguous genitalia at birth and affects male sexual development, but individuals often develop male characteristics at puberty.
9 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Recognizing Jacquet's sign helps diagnose and treat traction alopecia accurately.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
February 2026 in “Frontiers in Medicine” Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.
1 citations
,
November 2023 in “Rice” PRX102 is essential for rice root hair growth by helping transport substances to the tips.
January 2023 in “RSC Advances” The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.
Hair loss significantly lowers life quality, especially in young men, with most patients unhappy with treatment effectiveness.
2 citations
,
September 2007 in “International Journal of Impotence Research” Local testosterone treatment improved sexual desire in a female with fragile X syndrome.
April 2025 in “Tạp chí Y Dược học Cần Thơ” Hair loss and mental health issues like anxiety and insomnia affect each other, impacting quality of life.
March 2017 in “BJU international” The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.
20 citations
,
February 2010 in “Journal of Investigative Dermatology” Slug (Snai2) helps regulate hair growth timing in mice.
August 2024 in “American Journal of Medical Genetics Part A” Variants in the CCDC47 gene are linked to trichohepatoneurodevelopmental syndrome.
4 citations
,
January 2019 in “Skin appendage disorders” The new Follicular Map method could help assess hair treatment effectiveness but has some limitations.
April 2016 in “Journal of The American Academy of Dermatology” AGA patients have a lower quality of life than AA patients.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
3 citations
,
January 2012 The method accurately measures Tamsulosin and Finasteride in medication and is suitable for regular quality checks.
October 1977 in “Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)” Mefloquine was generally safe at 500 mg weekly, but higher doses caused nausea and diarrhea.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
3 citations
,
June 2013 in “Journal of Dermatology” Hairpieces improve quality of life for women with hair loss.
Technology enhances human design thinking, creating new possibilities.
December 2017 in “Journal of Medical Science And clinical Research” The PCOS questionnaire is valid for Indian women, but metformin doesn't significantly improve symptoms beyond oral contraceptives.
3 citations
,
July 2016 in “Tropical Journal of Pharmaceutical Research” Splitting non-scored tablets can lead to uneven drug distribution, posing risks.
June 2026 in “Journal of health economics and outcomes research” The study conducted a cost-per-responder analysis comparing ritlecitinib and baricitinib for treating severe alopecia areata. Ritlecitinib, a JAK3/TEC inhibitor, showed greater efficacy and a lower cost per responder than baricitinib, a JAK1/2 inhibitor, at both Weeks 24 and 52. Specifically, 52.10% of ritlecitinib initiators achieved a significant response by Week 24 compared to 36.28% for baricitinib. By Week 52, 40.26% of ritlecitinib users reached the desired outcome versus 30.63% for baricitinib. The cost per responder was lower for ritlecitinib at both time points, suggesting it may be a more cost-effective option for inclusion in treatment plans for severe alopecia areata.
1 citations
,
December 2005 in “The Journal of Urology” Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
16 citations
,
December 2007 in “Expert Review of Pharmacoeconomics & Outcomes Research” PCOS lowers quality of life, causing issues like obesity, infertility, and menstrual problems.
October 2023 in “Lithuanian University of Health Sciences” The TG5 gene affects beef cattle weight, and the CC genotype leads to higher weights.
6 citations
,
August 2020 in “JCRPE” A boy with a rare form of early puberty caused by a new gene mutation responded well to treatment aimed at reducing testosterone and preserving adult height.